Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7179650: Compositions and uses for a novel cell-death-protecting protein

Share

Filing Information

Inventor(s) Edward T. H. Yeh ·
Assignee(s) Board of Regents, the University of Texas System ·
Attorney/Agent(s) Fulbright & Jaworski LLP ·
Primary Examiner Anne M. Wehbe′ ·
Application Number US9484964
Filing date 01/18/2000
Issue date 02/20/2007
Predicted expiration date 11/04/2017
U.S. Classifications 435/455  · 435/320.1  · 435/325  ·
International Classifications C12N1563  · C12N1574  · C12N500  ·
Kind CodeB1
Related U.S. Application Data1.0 BACKGROUND OF THE INVENTION
This application is a divisional of U.S. patent application Ser. No. 08/964,162, now abandoned, filed on Nov. 4, 1997, which is a continuing application of U.S. Provisional Application Ser. No. 60/030,302, filed Nov. 5, 1996, the content of which is specifically incorporated herein by reference in its entirety.
6 Claims, 21 Drawings


Abstract

Disclosed are compositions comprising a novel cell-death protecting protein, sentrin-1, and the gene which encodes it. Also disclosed are methods of making and using sentrin polypeptides and nucleic acid segments in various diagnostic and pharmaceutical applications. In a preferred embodiment, overexpression of sentrin-1 confers protection against both anti-Fas/APO-1 and TNF-induced apoptosis.

Independent Claims | See all claims (6)

  1. 1. A method of inhibiting apoptosis in a cell comprising providing, in vitro, the cell with a nucleic acid segment encoding a polypeptide comprising SEQ ID NO:2, wherein a Fas and/or TNFR1 mediated apoptosis pathway is inhibited in the cell.
  2. 4. A method of inhibiting apoptosis in a cell comprising providing, in vitro, the cell with a nucleic acid segment comprising at least SEQ ID NO:1, wherein a Fas and/or TNFR1 mediated apoptosis pathway is inhibited in the cell.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US4196265 The Wistar Institute Koprowski et al. Apr 1980
US4554101 New York Blood Center, Inc. Hopp Nov 1985
US4683195 Cetus Corporation Mullis et al. Jul 1987
US4683202 Cetus Corporation Mullis Jul 1987
US4757011 E. I. Du Pont De Nemours and Company Chaleff et al. Jul 1988
US4769061 Calgene Inc. Comai Sep 1988
US4940835 Monsanto Company Shah et al. Jul 1990
US4965188 Cetus Corporation Mullis et al. Oct 1990
US4971908 Monsanto Company Kishore et al. Nov 1990
US5176995 Hoffmann-La Roche Inc. Sninsky et al. Jan 1993
US5384253 DeKalb Genetics Corporation Krzyzek et al. Jan 1995

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
WO199531544Nov 1995

Other Publications

Orkin et. al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.*
Lieberthal et. al.; Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury, 1996, Invited Review : F477-F488.*
Lavin et. al.; Role of protein kinase activity in apoptosis, 1996, Experiential 52:979-994.*
Marshall; Gene Therapy's Growing Pains, 1995, Science, vol. 269: 1050-1055.*
Verma et. al.; Gene therapy- promises, problems and prospects, 1997, Nature vol. 389: 239-242.*
Boddy et al., “PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia”, Oncogene, 13:971-982, 1996.
Cenciaelli et al., “T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation,” J. Biol. Chem., 271(15):8709-8713, 1996.
Chinnaiyan et al., “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis,” Cell, 81:505-512, 1995.
Chinnaiyan et al., “FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis,” J. Biol. Chem., 271(9):4961-4965, 1996.
Chu et al., “A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis,” Proc. Natl. Acad. Sci. USA, 92:11894-11898, 1995.
Coux et al., “Structure and functions fo the 20S and 26S proteasomes,” Annu. Rev. Biochem., 65:801-847, 1996.
Darnay et al., “Identification of a protein kinase associated with cytoplasmic domain of the p60 tumor necrosis factor receptor,” J. Biol. Chem., 269(32):20299-20304, 1994.
Finley et al., “Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant,” Mol. Cell. Biol., 14(8):5501-5509, 1994.
Görlich et al., “Nucleocytoplasmic transport,” Science, 271:1513-1518, 1996.
Göttlicher et al., “Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor,” Steroids, 61:257-262, 1996.
Hateboer et al., “mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect,” J. Biol. Chem., 271(42):25906-25911, 1996.
Hsu et al., “TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways,” Cell, 84:299-308, 1996a.
Hsu et al. “TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1,” Immunity, 4:387-396, 1996b.
Kamitani et al., “Characterization of NEED8, a developmentally down-regulated ubiquitin,” J. Biol. Chem., 272(45):28557-28562, 1997b.
Kamitani et al., “Preferenctial modification of nuclear proteins by a novel ubiquitin-like molecule,” J. Biol. Chem., 272(22):14001-14004, 1997.
Kho et al., “Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A,” J. Biol. Chem., 272(6):3845-3851, 1997.
Kischkel et al., “Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor,” EMBO J., 14(22):5579-5588, 1995.
Mannen et al., “Cloning and expression of human homolog HSMT3 to yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene,” Biochem. Biophy. Res. Comm., 222:178-180, 1996.
Muzio et al., “FLICE, novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex,” Cell, 85:817-827, 1996.
Nuber et al., “Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5,” J. Biol. Chem., 271(5):2795-2800, 1996.
Saitoh et al., “RanBP2 associates with Ubc9p and a modified form of RanGAP1,” Proc. Natl. Acad. Sci. USA., 94:3736-3741, 1997.
Stanger et al., “RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death,” Cell, 81:513-523, 1995.
Takayama et al., “Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity,” Cell, 80:279-284, 1995.
Wang et al., “Molecular cloning of a cNDA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9,” J. Biol. Chem., 271(40):24811-24816, 1996.
Ayala et al., “Mendelain Genetics,” In: Modern Genetics, 2nd Edition, Menlo Park, California, Benjamin/Cummings Publishing Co., Inc., Chapter 2, p. 44, 1984.
Darnell et al., In: Molecular Cell Biology, Scientific American Books, New York, pp. 77-80 and 248-257, 1986.
Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H98111, Hellier et al., “The WashU-Merck EST Project,” yx09d11.sl Homo sapiens cDNA clone 261237 3′. Dec. 12, 1995.
Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H24103, Hellier et al., “The WashU-Merck EST Project,” ym50b07.rl Homo sapiens cDNA clone 51818 5′. Jul. 6, 1995.
International Search Report dated Mar. 11, 1998 (PCT/US97/20344)(UTFH:238P).
Shen et al., “UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins,” Genomics, 36(2):271-279, 1996.
Matunis et al., “A novel ubiquitin-like modification modulates the partitioning of the ran-GTpase-activating protein Ran GAP1 between the Cytosol and the nuclear pore complex,” J. Cell Biol., 135(6):1457-1470, 1996.
Okura et al., “Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, Sentrin,” J. Immunol., 157(10):4277-4281, 1996.
Shen et al., “Associations of UBE21 with RAD52, UBL1, p. 53, and RAD51 proteins in a yeast two-hybrid systems,” Genomics, 37:183-186, 1996.
* cited by examiner

Referenced By

The current document is not referenced by other documents.